WSAVA announces support from Boehringer Ingelheim for key committees

0
310
Boehringer Ingelheim WSAVA
WSAVA president Dr Ellen van Nierop

Boehringer Ingelheim has signed up to become a Silver Partner of the World Small Animal Veterinary Association (WSAVA) and will support the work of the association’s Global Pain Council (GPC) and Oncology Working Group (OWG).

The GPC, chaired jointly by Drs Jo Murrell and Paulo Steagall, aims to create a global environment for companion animals in which pain is considered as the fourth vital sign and addressed appropriately. It launched an updated set of Global Guidelines for the Recognition, Assessment and Treatment of Pain at the end of 2022.

The OWG, chaired by Dr Ann Hohenhaus, is working to overcome regional disparities in the treatment of cancers in dogs and cats by providing continuing education (CE) and a range of additional resources, including fact sheets and an Oncology Glossary, to secure advances in the understanding and treatment of oncology globally.

“Pet ownership is on the rise and many people consider their animal companions to be part of the family. As result, they have high expectations of their veterinarians,” said Dr Erich Schoett, head of Global Marketing Pet Therapeutics and Vaccines at Boehringer Ingelheim. 

“At the same time, small animal medicine is advancing at a staggering pace. Veterinarians face a continuous need to upskill, adapt to new standards of care and to provide tailored health offerings at each stage of a pet’s life.

“We recognise the significant value WSAVA and its committees add to the global veterinary community and are delighted to join with them in fostering standardised, high quality veterinary care for small animals around in the world.” 

WSAVA president Dr Ellen van Nierop added: “It’s thanks to the support of our industry partners that we are able to deliver such a wide range of CE to our members and to campaign on the global stage on issues that concern them, such as the global inequity in access to veterinary medicines.

“We’re absolutely delighted to welcome Boehringer Ingelheim as a Silver Partner and thank them very much for their support. We look forward to working with them during 2024 and beyond.”

Previous articleHow vet practices can best support neurodiversity
Next articleFurry friends responsible for over 12,000 injury hospitalisations in 2021–22

LEAVE A REPLY

Please enter your comment!
Please enter your name here